Search

Corcept Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

74.19 1.2

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

71.31

Max

76.23

Galvenie mērījumi

By Trading Economics

Ienākumi

75M

43M

Pārdošana

91M

256M

P/E

Sektora vidējais

178.8

51.78

EPS

0.36

Peļņas marža

16.782

Darbinieki

730

EBITDA

91M

47M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+127.77% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.1B

8.7B

Iepriekšējā atvēršanas cena

72.99

Iepriekšējā slēgšanas cena

74.19

Corcept Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. nov. 21:01 UTC

Corcept Therapeutics shares are significantly lower amid high market volume, trading well below its 20-day moving average and nearing the lower end of its one-month range.

2026. g. 9. nov. 21:07 UTC

Corcept Therapeutics is trading higher, reflecting broader market gains amid positive sentiment from Federal Reserve officials and unusually high trading volume today.

2026. g. 6. nov. 20:52 UTC

News

Corcept Therapeutics shares are advancing after reporting a third-quarter net income of $126.78 million and diluted EPS of $1.01, despite earlier session pullbacks.

2026. g. 5. nov. 21:03 UTC

News

Selling pressure after 13.16k shares sold, lower sales guidance reaffirmed.

2026. g. 4. nov. 21:02 UTC

News

Corcept Therapeutics' Overweight rating was reaffirmed by Piper Sandler, which raised its price target to $173, despite disappointing revenue guidance for 2026.

2026. g. 3. nov. 23:01 UTC

News

Corcept Therapeutics reported Q3 revenue of $340.5 million and net income of $126.8 million, but reiterated full-year guidance of $1.1 billion to $1.2 billion.

2026. g. 2. nov. 21:09 UTC

Corcept Therapeutics shares are declining, continuing a trend of modest losses since Friday, as the broader market also experiences its fifth consecutive session of declines.

2026. g. 30. okt. 20:02 UTC

Corcept Therapeutics shares are sharply lower, reversing a trend of higher daily closes observed in recent sessions.

2026. g. 28. okt. 19:51 UTC

Corcept Therapeutics shares are declining, trading significantly below its 20-day moving average and near the lower end of its one-month range.

2026. g. 27. okt. 19:36 UTC

Corcept Therapeutics shares are advancing, having regained ground after pulling back earlier in the session, with a slight cumulative return since Monday's close.

2026. g. 26. okt. 23:21 UTC

Corcept Therapeutics Inc is trading lower in after-hours, remaining near the lower end of its one-month range and significantly below its 20-day moving average.

2026. g. 23. okt. 23:51 UTC

Corcept Therapeutics Inc is rising in after-market trading, recovering from an earlier dip to its highest point of the day despite recent declines.

2026. g. 22. okt. 20:02 UTC

Corcept Therapeutics Inc shares fell sharply, breaking from a recent trend of higher daily closes and indicating a downward shift in momentum.

2026. g. 20. okt. 20:08 UTC

News

Corcept Therapeutics shares gained following a report recommending hypercortisolism screening in type 2 diabetes, citing positive results from its CATALYST study on mifepristone.

2026. g. 16. okt. 20:01 UTC

Corcept Therapeutics Inc shares fell sharply, marking a notable decline and extending a streak of four consecutive sessions closing lower.

2026. g. 15. okt. 20:02 UTC

Corcept Therapeutics Inc shares are declining, having reached their lowest point around mid-afternoon after an early peak earlier in the session.

2026. g. 14. okt. 19:53 UTC

Corcept Therapeutics Inc shares fell sharply, continuing a downward trend since Tuesday's close, despite peaking in the late morning.

2026. g. 9. okt. 19:55 UTC

Corcept Therapeutics Inc is trading higher, having gained notably since Thursday's close and currently positioned above its 20-day moving average.

2026. g. 7. okt. 19:35 UTC

Corcept Therapeutics Inc is trading modestly higher, positioned significantly above its 20-day moving average and near the upper end of its one-month range.

2026. g. 6. okt. 23:55 UTC

Corcept Therapeutics Inc is trading higher in after-market hours, remaining above its 20-day moving average following a significant U.S. trade deficit of $105.6 billion in August.

2026. g. 5. okt. 20:01 UTC

Corcept Therapeutics Inc is trading sharply higher with unusually high share volume, nearing the upper end of its one-month trading range.

2026. g. 1. okt. 20:08 UTC

Corcept Therapeutics Inc shares fell sharply, declining from Wednesday's close and reaching a low before slightly recovering, remaining in the middle of its one-month trading range.

2026. g. 30. sept. 20:01 UTC

Corcept Therapeutics Inc is seeing higher trading activity with increased market volume and has gained ground since Tuesday, reaching a session high today.

2026. g. 29. sept. 20:07 UTC

Corcept Therapeutics Inc shares fell, continuing a trend with four consecutive sessions down since Monday, despite an earlier brief rebound.

2026. g. 28. sept. 19:34 UTC

Corcept Therapeutics Inc shares fell sharply amid a broader market downturn, coinciding with significant declines in major tech stocks and rising inflation concerns.

2026. g. 25. sept. 19:15 UTC

Corcept Therapeutics Inc shares fell sharply after an early high, reflecting a notable decline amid mixed broader market signals and flat U.S. durable goods orders.

2026. g. 24. sept. 23:06 UTC

Corcept Therapeutics Inc is trading lower during after-market hours, reflecting a broader market decline despite some recovery from earlier lows.

2026. g. 23. sept. 20:04 UTC

News

Corcept Therapeutics shares fell following the announcement of Sean Maduck's retirement as President of Endocrinology, with Justin Gunn set to take over.

2026. g. 22. sept. 19:34 UTC

News

Corcept Therapeutics' stock is advancing after the European drug regulator recommended approval for its cancer therapy, relacorilant, based on positive Phase 3 trial data.

2026. g. 21. sept. 20:06 UTC

Corcept Therapeutics Inc is advancing, maintaining significant gains since Friday's close, despite earlier pulling back from a session high.

Salīdzinājums

Cenas izmaiņa

Corcept Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

127.77% augšup

Prognoze 12 mēnešiem

Vidējais 165.75 USD  127.77%

Augstākais 173 USD

Zemākais 161 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Corcept Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

4

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat